Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic

Angiology

Volumn 66, Issue 4, 2015, Pages 346-353

  Barkas, Fotios ^a   Liberopoulos, Evangelos N ^a   Kostapanos, Michael S ^a   Liamis, George ^a   Tziallas, Dimitrios ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

cardiovascular disease; dyslipidemia; guidelines; high risk; lipid clinic; low density lipoprotein cholesterol; treatment target

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; COLESEVELAM; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; URIC ACID; ANTILIPEMIC AGENT; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; AGED; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; COMPLICATION; DRUG COMBINATION; DYSLIPIDEMIAS; GREECE; MIDDLE AGED; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; RISK FACTOR; TIME; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; GREECE; GUIDELINE ADHERENCE; HOSPITALS, UNIVERSITY; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927521244     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714535073     Document Type: Article

References (49)

1. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 ; 33 (13). 1635-1701
2. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS). Atherosclerosis. 2011 ; 217 (1). 3-46
3. Wong ND, Chuang J, Wong K, Pham A, Neff D, Marrett E. Residual dyslipidemia among united states adults treated with lipid modifying therapy (data from national health and nutrition examination survey 2009-2010). Am J Cardiol. 2013 ; 112 (3). 373-379
4. Kotseva K, Wood D, De Backer G, et al. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (5). 530-540
5. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 ; 373 (9667). 929-940
6. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (2). 121-137
7. EUROASPIRE IV: Adverse lifestyle trends counter improvements in CV risk factor management. http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/adverse-lifestyle-trends-counter-improvements-CV-risk-factor-management.aspx. Accessed December 8, 2013.
8. Elisaf MS, Nikas N. Centralized pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs-the CEPHEUS-greece survey. Angiology. 2010 ; 61 (5). 465-474
9. Liberopoulos E, Vlasserou F, Mitrogianni Z, Papageorgantas I, Elisaf M. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology. 2012 ; 63 (3). 184-193
10. Athyros VG, Liberopoulos EN, Mikhailidis DP, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology. 2007 ; 58 (6). 689-697
11. Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002 ; 106 (25). 3143-3421
12. Elisaf M, Pitsavos C, Liberopoulos E, Athyros V. Guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia. Hellenic J Atherosclerosis. 2011 ; 2 (3). 163-168
13. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003 ; 168 (1). 1-14
14. Chin CW, Gao F, Le T, Tan R. Lipid goal attainment and prescription behavior in Asian patients with acute coronary syndromes: experience from a tertiary hospital. Clin Med Insights Cardiol. 2013 ; 7: 51-57
15. Pirro M, Del Giorno R, Lupattelli G, et al. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic. Eur J Intern Med. 2011 ; 22 (4). 412-417
16. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the national health and nutrition examination survey 2003-2004. Am Heart J. 2008 ; 156 (1). 112-119
17. Malik S, Lopez V, Chen R, Wu W, Wong ND. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007 ; 77 (1). 126-133
18. Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005 ; 70 (3). 263-269
19. Nag SS, Daniel GW, Bullano MF, et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 2007 ; 13 (8). 652-663
20. Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007 ; 100 (10). 1499-1501
21. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012 ; 1 (6). e001800
22. Yu BL, Zhao SP, Peng DQ, Huo Y, Hu L. A comparison of non-HDL and LDL cholesterol goal attainment in the CHILLAS trial. Int J Cardiol. 2013 ; 168 (4). 4340-4342
23. Santos RD, Waters DD, Tarasenko L, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the lipid treatment assessment project 2. Atherosclerosis. 2012 ; 224 (1). 150-153
24. Olsson AG, Lindahl C, Holme I, et al. LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. Eur J Cardiovasc Prev Rehabil. 2011 ; 18 (2). 262-269
25. Melloni C, Shah BR, Ou FS, et al. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the medications applied aNd SusTAINed over time (MAINTAIN) registry. Am Heart J. 2010 ; 160 (6). 1121-1129
26. Ferrieres J, Amber V, Crisan O, Chazelle F, Junger C, Wood D. Total lipid management and cardiovascular disease in the dyslipidemia international study. Cardiology. 2013 ; 125 (3). 154-163
27. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in get with the guidelines. Am Heart J. 2009 ; 157 (1). 111-117
28. Schaefer JR, Gitt AK, Sonntag F, et al. Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA registry. Vasc Health Risk Manag. 2013 ; 9: 71-80
29. Stadler SL, Bhardwaja B, Olson KL, Powers JD, Lanese D. An assessment of cholesterol goal attainment in patients with chronic kidney disease. J Clin Lipidol. 2010 ; 4 (4). 298-304
30. Kumar A, Fonarow GC, Eagle KA, et al. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH registry. Crit Pathw Cardiol. 2009 ; 8 (3). 104-111
31. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007 ; 28 (2). 154-159
32. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek atorvastatin and coronary heart disease evaluation (GREACE) study. Nephrol Dial Transplant. 2007 ; 22 (1). 118-127
33. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010 ; 376 (9756). 1916-1922
34. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004 ; 57 (7). 728-734
35. Baessler A, Fischer M, Huf V, et al. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol. 2005 ; 101 (2). 293-298
36. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008 ; 7 (6). 717-725
37. Barkas F, Liberopoulos E, Elisaf M. Impact of compliance with antihypertensive and lipid-lowering treatment on cardiocascular risk - Benefits of fixed-dose combinations. Hellenic J Atherosclerosis. 2013 ; 4 (1). 31-39
38. Athyros VG, Elisaf MS, Alexandrides T, et al. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology. 2012 ; 63 (5). 358-366
39. Sager HB, Linsel-Nitschke P, Mayer B, et al. Physicians' perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients. Eur Heart J. 2010 ; 31 (10). 1266-1273
40. Buyken AE, von Eckardstein A, Schulte H, Cullen P, Assmann G. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil. 2007 ; 14 (2). 230-236
41. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009 ; 26 (2). 142-148
42. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012 ; 380 (9844). 807-814
43. Bestehorn K, Jannowitz C, Karmann B, Pittrow D, Kirch W. Characteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in disease management program versus those in routine care: LUTZ registry. BMC Public Health. 2009 ; 9: 280
44. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 ; 326 (7404). 1423
45. Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmology. 2013 ; 131 (11). 1427-1434
46. Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the Treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009 ; 104 (4). 459-463
47. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin. 2009 ; 25 (10). 2571-2576
48. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2013 2014 ; 129: S1 - S45
49. Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol. 2014 ; 11 (2). 72-74